Dichloro- bis -(pyridine-2-yl-undecylamine) zinc(II), [ZnCl 2 (C 16 N 2 H 26 ) 2 ]. Synthesis, characterization and antimalarial activity by Abu Ali, Hijazi et al.
See	discussions,	stats,	and	author	profiles	for	this	publication	at:	https://www.researchgate.net/publication/304338760
Dichloro-	bis	-(pyridine-2-yl-undecyl-
amine)zinc(II),	[ZnCl	2	(C	16	N	2	H	26	)	2	].
Synthesis,	characterization	and	antimalarial
activity
Article		in		Journal	of	Coordination	Chemistry	·	June	2016
DOI:	10.1080/00958972.2016.1204443
CITATIONS
0
READS
48
5	authors,	including:
Hijazi	Abu	Ali
Birzeit	University
58	PUBLICATIONS			331	CITATIONS			
SEE	PROFILE
Salam	Maloul
Birzeit	University
4	PUBLICATIONS			12	CITATIONS			
SEE	PROFILE
Mutaz	Akkawi
Al-Quds	University
40	PUBLICATIONS			375	CITATIONS			
SEE	PROFILE
Suhair	Jaber
Al-Quds	University
13	PUBLICATIONS			24	CITATIONS			
SEE	PROFILE
All	content	following	this	page	was	uploaded	by	Hijazi	Abu	Ali	on	23	July	2016.
The	user	has	requested	enhancement	of	the	downloaded	file.	All	in-text	references	underlined	in	blue	are	added	to	the	original	document
and	are	linked	to	publications	on	ResearchGate,	letting	you	access	and	read	them	immediately.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=gcoo20
Download by: [Hijazi Abu Ali] Date: 20 July 2016, At: 07:48
Journal of Coordination Chemistry
ISSN: 0095-8972 (Print) 1029-0389 (Online) Journal homepage: http://www.tandfonline.com/loi/gcoo20
Dichloro-bis-(pyridine-2-yl-undecyl-amine)zinc(II),
[ZnCl2(C16N2H26)2]: Synthesis, characterization and
antimalarial activity
Hijazi Abu Ali, Salam Maloul, Issa Abu Ali, Mutaz Akkawi & Suhair Jaber
To cite this article: Hijazi Abu Ali, Salam Maloul, Issa Abu Ali, Mutaz Akkawi & Suhair Jaber
(2016) Dichloro-bis-(pyridine-2-yl-undecyl-amine)zinc(II), [ZnCl2(C16N2H26)2]: Synthesis,
characterization and antimalarial activity, Journal of Coordination Chemistry, 69:16, 2514-2522,
DOI: 10.1080/00958972.2016.1204443
To link to this article:  http://dx.doi.org/10.1080/00958972.2016.1204443
View supplementary material 
Accepted author version posted online: 22
Jun 2016.
Published online: 07 Jul 2016.
Submit your article to this journal 
Article views: 22
View related articles 
View Crossmark data
Journal of Coordination Chemistry, 2016
Vol. 69, no. 16, 2514–2522
http://dx.doi.org/10.1080/00958972.2016.1204443
Dichloro-bis-(pyridine-2-yl-undecyl-amine)zinc(II), 
[ZnCl2(C16N2H26)2]: Synthesis, characterization and antimalarial 
activity
Hijazi Abu Alia,†, Salam Maloula,†, Issa Abu Alib, Mutaz Akkawic and Suhair Jaberc
adepartment of Chemistry, Birzeit university, West Bank, Palestine; bdoctor of Pharmacy Program, Birzeit university, 
West Bank, Palestine; cdepartment of life sciences, al-Quds university, West Bank, Palestine
ABSTRACT
A nitrogen-based ligand (pyridine-2-yl-undecyl-amine) (1) was synthesized 
and used for the synthesis of a Zn(II) compound (dichloro-bis(pyridine-2-yl-
undecyl-amine)zinc(II)) (2). Compound 2 was synthesized and characterized 
using IR, 1H NMR, and 13C{1H} NMR spectroscopy. The crystal structure of 2 was 
determined using single-crystal X-ray crystallography. The compound was 
tested for its anti-malarial activity using two methods, a semi-quantitative 
micro-assay and a previously self-developed quantitative in vitro method. 
Both methods were used to study the efficiency of 2 to inhibit the formation 
of the malaria pigment considered an important target of many anti-malarial 
drugs such as chloroquine and amodaquine. The efficiency of 2 to prevent 
the formation of β-hematin was 71.4%. The efficiency of amodiaquine as a 
standard drug was reported at 93.8%.
1. Introduction
Zinc plays a very important role in the living body [1]. Zinc occurs naturally as the divalent cation Zn2+ 
and has no redox activity under physiological conditions. Zn(II) is a strong intracellular Lewis acid, 
coordinating to proteins via either the cysteine residues or the amino ligands of histidine residues or 
sulfur “thiol” moieties [2].
Many nitrogen-based ligands have been synthesized and their biological activity studied [3–9]. 
Studies have shown that heterocyclic nitrogen plays an important role in coordination chemistry. 
Heterocycles which contain more than one nitrogen are key structures in a large variety of biochemical 
processes. These ligands exhibit various coordination modes in metal complexes [10, 11].
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different studies have shown that the interaction of metal ions with bioactive organic compounds 
increases the biological activity of the ligands [3, 12]. Many factors determine the relationship between 
the structure and activity of the compounds. Among these factors are the metal oxidation state, the 
type and number of donors, as well as their relative position within the ligands [3, 13].
Malaria is a prevalent parasitic disease. As reported by the World Health organization and according 
to the World Malaria Report of 2015 [14], Africa is the most affected continent with about 91% of all 
malarial deaths [15]. Plasmodium, the parasite causing malaria, is the single most devastating protozoan 
[16]. There are five species of plasmodium that may cause human malaria, but plasmodium falciparum 
is the most fatal species [17].
The parasite lives within human red blood cells and consumes over two-thirds of the hemoglobin of 
the host cell [18]. during its intraerythrocytic stage, the parasite degrades hemoglobin for its biosyn-
thetic requirements. Large amounts of free heme known as ferriprotoporphyrin (IX) are released [17]. 
The accumulation of ferriprotoporphyrin (IX) causes the generation of reactive oxygen species which 
may induce oxidative stress leading to parasitic death [15]. The parasite avoids these toxic effects by 
polymerizing these heme molecules within the food vacuole at pH 4.5–5.0, into a nontoxic, unreactive, 
insoluble crystalline compound called hemozoin or “malaria pigment” [17]. Hemozoin formed in this 
unique life cycle is an important target in the search of new antimalarial drugs [19, 20]. A synthetic analog 
to hemozoin called β-hematin is structurally and spectroscopically identical to purified hemozoin [19], 
making it an excellent target for biochemistry studies [21]. Structurally, hemozoin consists of reciprocal 
head-to-tail dimeric units of heme bound through propionate oxygen-iron(III) [19, 21]. The propionic 
acid groups of the heme dimer are then hydrogen bonded with other dimers to form extended crystals. 
Since it is a process that is essential to the survival of the malaria parasite, it acts as an excellent target 
for in vitro study. drugs are thought to act by inhibiting the formation of hemozoin in the food vacuole 
of the parasite. This prevents detoxification of the free heme released in this compartment, killing thus 
the parasite [19, 21].
Ring-used heterocycles which contain more than one nitrogen are key structures in a large variety of 
biochemical processes [10]. Compounds may coordinate through the exocyclic amino group attached 
directly to the ring or more probably through nitrogen of the endocyclic ring. either way the mecha-
nism of inhibition is thought to be through complexation which prevents the formation of β-hematin. 
Chloroquine, a quinoline-ring drug, is widely used for malaria treatment, and it inhibits heme polym-
erization “β-hematin formation” through complex formation with ferriheme monomers [22].
However, resistance to chloroquine has increased, owing to extensive and uncontrolled use. 
Chloroquine resistance and toxicity are considered as major challenges, and the need for new effective 
antimalarial drugs exists [23]. In this study, we describe the structure and the antimalarial activity of a 
new zinc chloride with nitrogen-based ligand. The ligand contains both hydrophilic and hydrophobic 
groups, which play a crucial role in its structure activity relationship. The crystal structure, spectroscopic 
properties, and antimalarial potential of 2 are reported.
2. Results and discussion
2.1. Synthesis
Compound 1 was prepared by reacting 1 eq of undecane bromide with 1 eq of 2-aminopyridine in THf. 
The desired product was obtained as a yellow precipitate. Compound 2 was synthesized by mixing 1 
with ZnCl2 in THf; the residues were crystallized to give a white precipitate (scheme 1).
2.2. X-ray crystallographic study of [ZnCl2(pyridine-2-yl-undecyl-amine)2]
The geometry for 2 has been confirmed by single-crystal X-ray crystallography. figure 1 shows an oRTeP 
view of the molecule and Table S1 and Table 1 summarize atomic parameters and significant bond 
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lengths and angles, respectively. The zinc is four-coordinate generating a distorted tetrahedral coor-
dination environment. Two coordination sites are occupied by the N-donors of 1 while the remaining 
coordination sites are occupied by chlorides. However, the bond angle N(3)-Zn(1)–N(1) of 100.65(6)° is 
low for a typical tetrahedral geometry, resulting in a distortion [24, 25].
The two Zn–Cl distances Cl(1)–Zn(1) (2.2271(5) Å) and Cl(2)–Zn(1) (2.2367(5) Å), due to symmetry 
reasons, are approximately equal in length; they are similar to previously reported values [3, 24–28]. 
Compound 2 exhibits Zn–N bonds of the same length with values 2.0612(17) and 2.0504(15) Å.
Table S2 shows two intramolecular hydrogen bonds between N(2) and C1(1), N(4) and Cl(2) with dis-
tances of 3.331(2) and 3.3014(19) Å, respectively. These values are comparable with previously reported 
values in similar complexes [27]. This identical hydrogen bonding also supports the fact that the bond 
distances of Cl(1)–Zn(1) and Cl(2)–Zn(1) are similar, while in reported complexes there was lengthening 
of the Zn–Cl(1) bond related to the presence of an intramolecular hydrogen bond, since Cl(2) does not 
form such a bond [29].
Figure 1. View of the molecular structure of 2 showing the atom labeling scheme.
Table 1. selected bond distances (Å) and angles (°) for 2.
Bond distances (Å) Bond angles (°)
Cl(1)–Zn(1) 2.2271(5) n(3)–Zn(1)–n(1) 100.65(6)
Cl(2)–Zn(1) 2.2367(5) Cl(1)–Zn(1)–Cl(2) 114.20(2)
n(1)–Zn(1) 2.0612(17) C(1)–n(1)–Zn(1) 115.71(13)
n(3)–Zn(1) 2.0504(15) C(5)–n(1)–Zn(1) 125.63(13)
C(21)–n(4) 1.353(3) n(2)–C(5)–n(1) 117.63(19)
C(21)–n(3) 1.354(2) n(4)–C(21)–n(3) 117.52(17)
C(22)–n(4) 1.452(2) C(21)–n(4)–C(22) 123.59(18)
Br
N
+
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H2N THF,reflux
overnight
N
H
N
Zn
Cl Cl
N
H
N
compound2
ZnC
l 2,
THF
3 d
ays
Scheme 1. synthesis of 1 and 2.
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2.3. Infrared and UV–vis spectra
The infrared (IR) frequencies from 4000 to 190 cm−1 and uV–vis bands for 2-aminopyridine in 1 and 2 are 
given in Table S3. The Zn–Cl and Zn–N stretching frequencies are at 300, 321 cm−1 and 205, 245 cm−1, 
respectively, and were assigned by comparison with those reported for similar complexes [30, 31]. As 
expected, the two peaks for vN–H in 2-aminopyridine (3330, 3205 m) were observed as one peak in 1 
and 2 and shifted to lower energy, confirming the formation of 1 and 2. This shift to lower energy may 
be due to hydrogen bond formation between the N–H hydrogen and chloride as supported by the 
crystal structure of 2 [30, 31].
The absorption spectrum of 2 in dMSo is very similar to that of the parent N-donor ligand with only 
1-nm shift caused by coordination to zinc. Thus, all bands of 2 are based to ligand. The spectra are also 
similar to zinc complexes of N-donor ligands [3, 26, 28].
2.4. 1H NMR and 13C {1H} NMR results
1H NMR and 13C{1H} NMR data and parameters of 2 and its parent ligand are listed in the section 4. for 
2, the NMR resonances and chemical shifts are supported by the X-ray structure. The NH resonance 
at 4.53 ppm is up-field shifted to 7.16 ppm in 2 due to complexation and hydrogen bonding with Cl−. 
The CH2NH resonance at 3.23 ppm is down-field shifted to 3.14 ppm in 2. The pyridine ring hydrogen 
resonances are almost identical in 2 and its parent ligand. The 13C{1H} NMR chemical shifts for 2 and its 
parent ligand are similar. However, the resonance for CH2NH at 42.30 ppm in the ligand was down-field 
shifted to 43.01 ppm in 2.
2.5. Antimalarial activity
Before measurement of its antimalarial activity, the solution stability of 2 was checked by 
recording periodically the 1H and 13C NMR spectra in chloroform and dMSo which always gave the 
same data. In addition, 2 was crystallized by slow solvent evaporation at room temperature that 
took several days, and the NMR measurements were repeated to give the same physical properties of 
the compound.
A semi-quantitative in vitro method developed by deharo et al. was used in this study [32]. 
In this microassay, the inhibitory effect of different compounds on the biomineralization of 
ferriprotoporphyrin IX to hemozoin or β-hematin was studied. It is based on the detection by optical 
density measurement of solubilized β-hematin remaining after contact with drugs. Positive controls 
such as chloroquine or amodiaquine will inhibit the formation of β-hematin and will give low absorb-
ance values.
2.5.1. Semi-quantitative method
Compound 2 was evaluated for its inhibitory effect on in vitro β-hematin formation. Results of the 
semi-quantitative method are shown in figure 2. The efficiency of the drug used is inversely propor-
tional to the absorption, since low absorption indicates higher efficiency. It is important to mention 
that each result is the average of 24 individual experiments. As shown in figure 2, 2 with an absorbance 
value of 0.157 (at a concentration of 1 mg mL−1) has a potential antimalarial activity when compared to 
the standard drugs, while no inhibition was noticed at 0.6 mg mL−1. This result is in accord with similar 
previously reported zinc complexes [26, 28].
2.5.2. Quantitative method
According to the method used, comparison of 2 with dMSo (as negative control) and amodiaquine 
(AQ as positive control) in terms of β-hematin formation is shown in figure 3. A comparison in terms of 
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drug efficiency is shown in figure 4. figure 3 represents the percentage yield of β-hematin formation. 
Interestingly, the percentage yield of β-hematin formation in the presence of 2 was 28.6% and that of 
AQ was 6.2%, both at 0.4 mM concentration comparing to the negative control which was 89.2%. A 
comparison in terms of efficiency of 2 is shown in figure 4. It is obvious that 2 has antimalarial activity 
in inhibiting β-hematin formation with efficiency of 71.4% when compared to AQ (93.8%) and dMSo 
(10.8%).
Figure 2.  Column diagram representing semi-quantitative test results of potential antimalarial drug [ZnCl2(2-aminopyridine-
dodecane)2] (2) compared to chloroquine (CQ), amodiaquine (aQ) (0.1 mg ml
−1), and 2-mercaptopyrimidine (1 mg ml−1) as positive 
controls, while water and dmso were used as negative controls. absorption is inversely proportional to drug efficiency; the lower 
absorption drug is considered to be more efficient. results are the average of 24 tests.
Figure 3. Column diagram representing the percentage yield of 2 compared to amodiaquine and dmso at 0.4 mm. yields are inversely 
proportional to drug efficiency; the lower yield drug is considered to be more efficient.
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3. Conclusion
Compound 2 and its parent ligand were synthesized and characterized by various spectrometric tech-
niques including X-ray crystallography, 1H NMR, 13C{1H} NMR, IR, and uV–vis. Compound 2 showed 
inhibition activity on the formation of β-hematin. ongoing research will be carried out in our laboratory 
to study the toxicity and the in vivo effects of this compound to gain further understanding of their 
biological action. The efficiency of 2 in preventing the formation of β-hematin was 71.4% compared 
to 93.8% of the standard drug amodiaquine. Compound 1 did not show any inhibition activity against 
β-hematin formation.
4. Experimental
4.1. Instruments
Infrared absorption spectra were recorded using a Varian 600 fT-IR spectrometer from 400 to 4000 cm−1 
using KBr pellets. 1H and 13C{1H} NMR spectra were recorded in CdCl3 and dMSo (d6) as solvents with a 
Varian unity spectrometer (300 and 75 Hz) for 1H and 13C{1H} nuclei, respectively. uV–vis spectra were 
recorded using a Hewlett Packard 8453 photo-diode array spectrophotometer from 200 to 4000 nm 
using dMSo as solvent. Melting points were determined in capillary tubes with eZ-melt apparatus and 
are uncorrected.
4.2. Materials
The starting materials used in the present work were purchased from Sigma-Aldrich with high purity 
and used without purification. Solvents were also purchased from commercial sources.
4.3. Synthesis
4.3.1. Synthesis of pyridine-2-yl-undecyl-amine (1)
undecane bromide (11.75 g, 0.0499 mol) dissolved in 20 ml THf was carefully added to a stirred 2-ami-
nopyridine solution (4.72 g, 0.05 mol) dissolved in 70 ml THf. The reaction mixture was heated under 
reflux overnight, and then the product was extracted using 2 M NaoH and ethyl acetate. The organic 
Figure 4. Column diagram representing the efficiency of 2 compared to amodiaquine and dmso, all at a concentration of 0.4 mm.
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layer was dried over anhydrous magnesium sulfate and solvent was removed under vacuum. The prod-
uct was purified by silica gel column chromatography with 5% ethyl acetate/petroleum ether as eluent 
to give the product as yellow solid.
C16N2H28 (1): 70% yield, m.p. 51 °C; 
1H NMR (CdCl3, δ (ppm)): 0.88 (t, 3H, CH3, 
3JH–H = 6.9 Hz), 1.26 (s, 
16H, CH2), 1.59 (p, 2H, CH2, 
3JH–H = 6.9 Hz), 3.23 (q, 2H, CH2, 
3JH–H = 6.0 Hz), 4.53 (s, 1H, NH), 6.36 (d, 1H, CH, 
3JH–H = 8.1 Hz), 6.53 (t, 1H, CH, 
3JH–H = 6.0 Hz), 7.40 (t, 1H, CH, 
3JH-H = 7.5 Hz), 8.06 (d, 1H, CH, 
3JH–H = 4.5 Hz), 
13C{1H} NMR (CdCl3, δ (ppm)): 14.11 (CH3), 22.69 (CH2), 27.07 (CH2), 29.33 (CH2), 29.41 (CH2), 29.55 (CH2), 
29.61 (CH2), 31.91 (CH2), 42.30 (CH2), 106.50 (Ar, CH), 112.55 (Ar, CH), 137.41(Ar, CH), 148.67 (Ar, CH), 158.50 
(Ar, C); IR (cm-1, KBr): 3268 (m, v(N–H)), 2923 (s, v(C–H)aromatic ), 2851 (s, v(C–H)aliphatic), 1604 (s, v(C=C)ring), 
1528 (s, v(C=C)ring), 802 (m, γ(C–H) aromatic). uV–vis, (dMSo, λ (nm)): 259, 275.
4.3.2. Synthesis of [ZnCl2(pyridine-2-yl-undecyl-amine)2] (2)
Pyridine-2-yl-undecyl-amine (0.496 g, 0.002 mol) dissolved in 20 mL THf was added to a stirred ZnCl2 
solution (0.272 g, 0.002 mol) dissolved in 30 mL THf. The reaction mixture was stirred at room temper-
ature for 3 days; then, the residue was washed with ethyl acetate, air-dried, and recrystallized from hot 
acetone to give colorless crystals.
[ZnCl2(C16N2H26)2] (2): 50% yield, m.p. 98 °C; 
1H NMR (CdCl3, δ (ppm)): 0.88 (t, 3H ,CH3, 
3JH-H = 6.6 Hz), 
1.25 (s, 16H, CH2), 1.40 (t, 2H, CH2, 
3JH–H = 7.5 Hz), 1.68 (p, 2H, CH2, 
3JH–H = 7.2 Hz), 3.14 (q, 2H, CH2, 
3JH–H = 3.9 Hz), 6.55 (d, 1H, CH, 
3JH–H = 8.1 Hz), 6.61 (t, 1H, CH, 
3JH-H = 5.7 Hz), 7.16 (s, 1H, NH), 7.61 (t, 1H, 
CH, 3JH–H = 7.5 Hz), 8.05 (d, 1H, CH, 
3JH–H = 4.5 Hz); 
13C{1H} NMR (CdCl3, δ (ppm)): 14.12 (CH3), 22.68 (CH2), 
26.97 (CH2), 28.55 (CH2), 29.29 (CH2), 29.33 (CH2), 29.53 (CH2), 29.61 (CH2), 31.90 (CH2), 43.01(CH2), 107.61 
(Ar, CH), 112.29 (Ar, CH), 124.23(Ar, CH), 146.32 (Ar, CH), 158.50 (Ar, C); IR (cm−1, KBr): 3301 (s, v(N–H)), 
2922 (s, v(C–H)aromatic), 2849 (s, v(C–H)aliphatic), 1617 (s, v(C=C)ring), 1574 (s, v(C=C)ring), 773 (m, γ(C–H)aromatic), 
245 (m, v(Zn–N)), 321 (m, v(Zn–Cl)). uV–vis (dMSo, λ (nm)): 259, 276.
4.4. X-ray crystallography
X-ray intensity data of 2 were obtained at room temperature on a Bruker SMART APeX CCd X-ray diffrac-
tometer system (graphite-monochromated Mo Kα radiation λ = 0.71073 Å) using the SMART software 
package [33]. The data were reduced and integrated by SAINT [34]. The structure was solved and refined 
by the SHeLXTL software package [35]. Hydrogens were located geometrically and treated with a rid-
ing model. Crystal data and details of the data collection and refinement are summarized in Table S1.
4.5. Antimalarial activity
4.5.1. In vitro testing for antimalarial activity using a semi-quantitative method
The procedure for in vitro testing was carried out according to deharo et al. [32]. A mixture containing 
50 mL of (0.5 mg mL−1) hemin chloride freshly dissolved in dMSo, 100 mL of (0.5 M) sodium acetate 
buffer (pH 4.4), and 50 mL of different concentrations of the compound dissolved in pure water was 
incubated in a normal nonsterile 96-well flat bottom plate at 37 °C for 18–24 h. It is important that the 
solutions be added to the plate in this order. The plate was then centrifuged for 10 min at 4000 rpm. The 
supernatant was removed and the pH of reaction was measured. The final pH of the mixture should be 
between 5.0 and 5.2. The wells were washed with 200 mL dMSo per well to remove free hemin chlo-
ride. The plate was centrifuged again, discarding the supernatant afterward. The residual β-hematin 
was then dissolved in 200 mL of 0.1 M NaoH to form ferriprotoporphyrin (IX) that can be measured 
spectrophotometrically. finally, the absorbance was measured at 405 nm using the eLISA reader. The 
results acquired were compared to negative ultrapure H2o and positive chloroquine (CQ) of 0.1 mg mL
−1 
and 2-mercaptopyrimidine (2-MP) of 1 mg mL−1 controls. 2-MP is considered as an internal control to 
ensure that the reaction environment was ideal, that is, due to its sensitivity to the change in temper-
ature. The absorption is inversely proportional to drug efficiency meaning the lower the absorption, 
the more efficient the drug.
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4.5.2. Quantitative test
The method of Blauer and Akkawi was adopted for quantitative test [36]. freshly prepared stock solution 
of hemin chloride was prepared by dissolving the salt in dMSo and incubating for 30 min at 30 °C; stock 
solution of the compound used was prepared using dMSo (0.5 M). Sodium acetate buffer (pH 4.4) was 
also prepared; the final concentration of hemin and the compound in the reaction were 0.2 and 0.4 mM, 
respectively. The whole mixture was left for 18–24 h at 37 °C without stirring. The total volume of the 
reaction mixture was 32 mL, and the final pH was 4.9–5.2. Samples were centrifuged for 10 min using a 
serological (Jouan B4) centrifuge. The supernatant was discarded and the precipitate was washed with 
dMSo and quantitatively transferred to a Millipore Swinnex 13 filter containing Whatman filter paper 
No. 50, already lyophilized to a constant weight in a freeze-drying machine (Labconco freezone). dMSo 
was passed slowly through the filter until the filtrate remained feebly colored and washed again with 
ultra-pure water. The remaining solid was then lyophilized to a constant weight.
Supplementary material
CCdC 1420242 (2) contains the supplementary crystallographic data for this paper. These data can be obtained free of 
charge from the Cambridge Crystallographic data Center via www.ccdc.cam.ac.uk/data_request/cif.
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